-

Abcore® Launches Naturally-Derived VHH Library Anti-T-Cell Platform

BOSTON--(BUSINESS WIRE)--Abcore®, a brand operating within the Antibody Solutions (AbS) business division as a part of Fortis Life Sciences®, an innovation leader in VHH discovery and single-domain-antibody library construction, announces the launch of AbNano™ Anti-T-Cell VHH Library, strengthening its VHH platform solutions. The Anti-T-Cell Library builds on the success of Abcore’s previously released AbNano™ Naïve VHH Library and expands innovative capabilities in immunology-focused research discovery.

The AbNano™ Anti-T-Cell Library is a first-in-class, naturally-derived VHH library designed for rapid identification of antibodies that bind to native T-cell surface proteins. With a target-binding population estimated one billion unique VHH molecules, the library enables direct access to novel binding profiles difficult and time consuming to generate using traditional methods.

“Abcore’s novel AbNano™ Anti-T-Cell Library enables rapid early therapeutic discovery for research labs, biotech companies, and pharma,” said Sam Sugerman, Director of VHH Discovery at Fortis Life Sciences. “By combining error-prone PCR diversification with whole, unstimulated T-Cells, Abcore has developed an effective library that reveals unique binding modalities applicable across bioprocessing, diagnostics and early-stage therapeutic discovery.”

T-Cells present unique challenges for antibody discovery due to the complex and context-sensitive nature of their surface proteins. The AbNano™ Anti-T-Cell library is an experimental solution that solves that challenge by utilizing:

  • Native T-Cell-based immunization strategy reducing late-stage attrition
  • Error-prone PCR (epPCR) diversification probing novel sequences
  • Diverse and atypical binding modes creating unique solutions
  • Validated key binders for critical targets, including CD3ε and CD8αβ

With applications spanning bioprocess optimization to preclinical therapeutic research discovery, the library is available to partners through Abcore’s early access program.

Flexible Engagement with Promotional Launch Packages

To support accelerated research discovery efforts, Abcore is offering limited-time promotional packages for partners to evaluate the AbNano™ VHH Libraries:

  • Solid-Phase Panning or Solution-Phase Panning

For ordering and further technical details, visit fortislife.com/libraries/abnano-anti-t-cell-vhh-library

About Abcore and Fortis Life Sciences

Founded in 2013 in Ramona, CA and acquired by Fortis Life Sciences in 2022, Abcore is an industry leader in phage display-based VHH library development. Fortis partners with diagnostics and life sciences companies to create, validate, and manufacture proprietary solutions to their most challenging problems. With end-to-end capabilities and a global footprint, Fortis accelerates innovation across biotherapeutics and diagnostics. To learn more, visit www.fortislife.com.

Contacts

Media
Christine Quern
cq@christinequern.com
617-650-8497

Fortis Life Sciences


Release Versions

Contacts

Media
Christine Quern
cq@christinequern.com
617-650-8497

More News From Fortis Life Sciences

Fortis Life Sciences acquires International Point of Care

BOSTON--(BUSINESS WIRE)--Fortis Life Sciences, LLC (“Fortis”) has acquired Toronto-based International Point of Care, Inc. (“IPOC”). IPOC develops and manufactures key components used in diagnostics, including lyophilized reagents, membranes, recombinant proteins, and controls. With this acquisition, Fortis can provide its customers with a customizable, end-to-end solution to advance their immunodiagnostic and molecular diagnostic products. IPOC’s recently expanded 36,000 sq. ft. facility is Fo...

Fortis Life Sciences Expands Its International Presence

WALTHAM, Mass.--(BUSINESS WIRE)--Fortis Life Sciences, a provider of high-quality reagents and custom services for discovery, development, and manufacturing, has expanded its international presence by opening an office in Seoul, South Korea. South Korea's pharmaceutical, diagnostic, and life science industry has grown to become one of the most comprehensive markets in Asia-Pacific, with increased demand from within and outside the region. Therefore, this strategic milestone is a significant dev...

Fortis Life Sciences Partners With AccuGenomics to Expand Genomics Portfolio

WALTHAM, Mass.--(BUSINESS WIRE)--Fortis Life Sciences, a strategic platform company providing capital, expertise, and operational resources to grow founder-led life science companies, today announced it is the exclusive channel partner for AccuGenomics in the Unites States, with co-exclusive rights in Europe. Under the agreement, Fortis will help expand customer access to AccuGenomics’ patented SNAQ™-SEQ Internal Standards technology, the only commercial internal standards for next-generation s...
Back to Newsroom